辛伐他汀联合卡维地洛用于食管胃静脉曲张出血一级预防的血流动力学影响:一项随机对照试验
结果显示联合治疗未提高HVPG应答率(61% vs 58.1%,P=0.85),未减少首次出血或死亡,辛伐他汀组有3.7%出现短暂转氨酶升高和肌酸磷酸激酶升高。
要点
- 辛伐他汀联合卡维地洛未改善3个月血流动力学应答。
- 联合治疗未减少首次出血或死亡事件。
- Child C肝硬化患者使用辛伐他汀需密切监测不良反应。
核心结论
- 在肝硬化食管静脉曲张一级预防中,卡维地洛加用辛伐他汀3个月未优于单药治疗的血流动力学应答。
研究设计与样本
- 前瞻性随机对照试验,纳入基线HVPG>12 mmHg的肝硬化食管静脉曲张患者,卡维地洛组110例,联合辛伐他汀组110例。
主要发现
- 3个月HVPG应答率两组相当(卡维地洛组36/62[58.1%],联合组36/59[61%],P=0.85)。
- 平均HVPG下降幅度分别为17.3%和17.8%(P=0.98),应答的OR为0.88(95%CI 0.43-1.83,P=0.74)。
- 达到目标心率且无低血压发作的患者血流动力学应答更好(77.8% vs 59.2%,P=0.04)。
- 未达到目标心率(OR 0.48,95%CI 0.22-1.06)和Child C肝硬化(OR 4.49,95%CI 1.20-16.8)预测无应答。
- 辛伐他汀组3例(3.7%)出现短暂转氨酶升高和肌酸磷酸激酶升高,停药后改善;两组各2例出血(P=0.99),死亡分别为3例和1例(P=0.32)。
临床怎么用
- 不推荐在卡维地洛基础上常规加用辛伐他汀用于食管静脉曲张出血一级预防。
- Child C肝硬化患者如使用辛伐他汀应密切监测肝酶和肌酸磷酸激酶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Beta-blockers are the mainstay agents for portal pressure reduction and to modestly reduce hepatic venous pressure gradient (HVPG). We studied whether addition of simvastatin to carvedilol in cirrhotic patients for primary prophylaxis improves the hemodynamic response. METHODS: Cirrhotic patients with esophageal varices and with baseline HVPG > 12 mm Hg were prospectively randomized for primary prophylaxis to receive either carvedilol (group A, n = 110) or carvedilol plus simvastatin (group B, n = 110). Primary objective was to compare hemodynamic response (HVPG reduction of ≥20% or <12 mm Hg) at 3 months, and secondary objectives were to compare first bleed episodes, death, and adverse events. RESULTS: The groups were comparable at baseline. The proportion of patients achieving HVPG response at 3 months was comparable between groups (group A-36/62 [58.1%], group B-36/59 [61%], P = 0.85). The degree of mean HVPG reduction (17.3% and 17.8%, respectively, P = 0.98) and hemodynamic response (odds ratio [OR]: 0.88; 95% confidence interval [CI]: 0.43-1.83, P = 0.74) was also not different between the groups. Patients who achieved target heart rate with no hypotensive episodes in either group showed better hemodynamic response (77.8% vs 59.2%, P = 0.04). Failure to achieve target heart rate (OR: 0.48; 95% CI: 0.22-1.06) and Child C cirrhosis (OR: 4.49; 95% CI: 1.20-16.8) predicted nonresponse. Three (3.7%) patients on simvastatin developed transient transaminitis and elevated creatine phosphokinase and improved with drug withdrawal. Two patients in each group bled (P = 0.99). Three patients and 1 patient, respectively, in group A and B died (P = 0.32), with sepsis being the cause of death. DISCUSSION: Addition of simvastatin to carvedilol for 3 months for primary prophylaxis of variceal bleeding does not improve hemodynamic response over carvedilol monotherapy. Simvastatin usage should be closely monitored for adverse effects in Child C cirrhotic patients.
引用
- Vijayaraghavan R, Jindal A, Arora V, et al. Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial. Am J Gastroenterol. 2020. PMID: 32079861. doi:10.14309/ajg.0000000000000551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。